👋No reviews yet — be the first!
Be the first verified prescriber to review JUVMO.
100% anonymous · NPI-verifiedFrom the official FDA prescribing information for JUVMO.
The active ingredient of JUVMO is tavapadon, a non-ergot dopamine agonist. The chemical name is (S)-1,5-dimethyl-6-(2-methyl-4-{[3-(trifluoromethyl) pyridin-2yl]oxy}phenyl)pyrimidine- 2,4(1H,3H)-dione. Its molecular formula is C19H16F3N3O3 and its molecular weight is 391.35 Daltons. The chemical structure is: Tavapadon is a white to pale-yellow solid that is practically insoluble in water. JUVMO tablets are intended for oral administration. Each film-coated tablet contains 0.25 mg, 1 mg, 5 mg, 10 mg, or 15 mg tavapadon. Inactive ingredients include: • 0.25 mg and 1 mg tablets: Lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, red iron oxide, sodium starch glycolate, talc, titanium dioxide, and yellow iron oxide. • 5 mg, 10 mg, and 15 mg tablets: Carmine, FD&C Blue No. 2, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, sodium starch glycolate, talc, and titanium dioxide.
JUVMO is indicated for the treatment of Parkinson’s disease (PD) in adults.
JUVMO (tavapadon) tablets are supplied in the following configurations: Tablet Strength Description Package Configuration NDC Code 5 mg Purple, film-coated, diamond, with “NRS” debossed on one side and “5” on the other side Bottle of 30 0074-6105-30 10 mg Purple, film-coated, oval, with “NRS” debossed on one side and “10” on the other side Bottle of 30 0074-6210-30 15 mg Purple, film-coated, rectangle, with “NRS” debossed on one side and “15” on the other side Bottle of 30 0074-6315-30 Titration Pack 0.25 mg: Orange, film-coated, round, with “NRS” debossed on one side and “025” on the other side 1 mg: Orange, film-coated, rectangle, with “NRS” debossed on one side and “1” on the other side Each carton contains 6 weekly blister cards containing the following total number of tablets: • Week 1 (ten x 0.25 mg tablets) • Week 2 (fourteen x 0.25 mg tablets and two x 1 mg tablets) • Week 3 (nine x 0.25 mg tablets and eight x 1 mg tablets) • Week 4 (three x 0.25 mg tablets and eighteen x 1 mg tablets) • Week 5 (twenty-one x 1 mg tablets) • Week 6 (fifteen x 1 mg tablets) 0074-6090-40 16.2 Storage and Handling Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].
2.1 Dosing Recommendations Administer JUVMO orally once daily with or without food. The recommended dosage and titration are included in Table 1. The JUVMO titration pack is recommended for patients initiating therapy with JUVMO to provide doses consistent with the recommended titration schedule to reach the 5 mg maintenance dosage [see How Supplied/Storage and Handling (16.1)]. Table 1: Recommended Dosage Titration Regimen* Treatment Days JUVMO Dosage Days 1 to 4 0.25 mg once daily Days 5 to 8 0.5 mg once daily Days 9 to 12 0.75 mg once daily Days 13 to 16 1 mg once daily Days 17 to 20 1.5 mg once daily Days 21 to 24 2.25 mg once daily Days 25 to 40 3 mg once daily Maintenance Dosage Day 41 and thereafter 5 mg once daily Maximum Dosage If needed, based on tolerability and clinical response, the maintenance dose may be increased in increments of 5 mg approximately every 15 days to the maximum recommended daily dosage. 15 mg once daily * Dose and titration should be guided by tolerability and clinical response. If required, longer intervals between dose adjustment can be used. 2.2 Dosage Modifications for CYP3A Inhibitors Strong or Moderate CYP3A Inhibitors [see Warnings and Precautions (5.3), Drug Interactions (7.1)] JUVMO Titration Avoid concomitant use of strong or moderate CYP3A inhibitors during titration of JUVMO. JUVMO Maintenance when Initiating Strong or Moderate CYP3A Inhibitors Follow the JUVMO dosage modifications in Table 2 when initiating a strong or moderate CYP3A inhibitor for patients already on JUVMO maintenance. Table 2: Dosage Modifications When Initiating a CYP3A Inhibitor in Patients Already on JUVMO Maintenance Current JUVMO Maintenance Dosage Recommended JUVMO Modification for Maintenance Dosage When Initiating a Strong CYP3A Inhibitor When Initiating a Moderate CYP3A Inhibitor 5 mg once daily 5 mg every 7 days 5 mg every 3 days 10 mg once daily 10 mg every 7 days 10 mg every 3 days 15 mg once daily 15 mg every 7 days 15 mg every 3 days Discontinuing CYP3A Inhibitors Upon discontinuation of the strong or moderate CYP3A inhibitor, resume the JUVMO maintenance dosage that was used prior to the initiation of the CYP3A inhibitor. Monitor patients for clinical response and tolerability. 2.3 Dosage Modifications for CYP3A Inducers Strong CYP3A Inducers [see Drug Interactions (7.1)] Avoid concomitant use of strong CYP3A inducers during titration and maintenance of JUVMO. Moderate CYP3A Inducers [see Drug Interactions (7.1)] Initiating JUVMO Titration and Maintenance when on Long-Term Moderate CYP3A Inducers Follow the JUVMO dosage modifications in Table 3 when initiating JUVMO titration and maintenance in patients who are already on long-term moderate CYP3A inducers. Table 3: Dosage Modifications for Patients Already on Moderate CYP3A Inducers Titration Regimen (requires two JUVMO titration packs)* Treatment Days JUVMO Dosage Days 1 to 4 0.25 mg twice daily Days 5 to 8 0.5 mg twice daily Days 9 to 12 0.75 mg twice daily Days 13 to 16 1 mg twice daily Days 17 to 20 1.5 mg twice daily Days 21 to 24 2.25 mg twice daily Days 25 to 40 3 mg twice daily Maintenance Dosage Day 41 and thereafter 5 mg twice daily Maximum Dosage If needed, based on clinical response and tolerability, the maintenance dosage may be increased to 5 mg three times a day. If further escalation is needed, the dose may be increased by 5 mg every 15 days, 45 mg daily (15 mg three times daily) administered in divided doses (either twice a day or three times a day), to the maximum recommended daily dosage. * Use one JUVMO titration pack for the morning dose and the second JUVMO titration pack for the evening dose. JUVMO Maintenance when Initiating Moderate CYP3A Inducers For patients who are already on JUVMO maintenance dosage and start to take moderate CYP3A inducers, modifications to JUVMO dosing are provided below: • Days 1 to 7 of concomitant use: continue the current maintenance dosage of JUVMO (5 mg, 10 mg, or 15 mg once daily). • Day 8 and thereafter during concomitant use: increase the frequency of the maintenance dosage of JUVMO to twice daily. If needed, based on clinical response and tolerability, the maintenance dosage can be increased to three times daily. Discontinuing CYP3A Inducers Upon discontinuation of moderate CYP3A inducers, gradually reduce the JUVMO dosage to once daily. Monitor patients for clinical response and tolerability. 2.4 Missed Dose If a dose of JUVMO is missed, take it as soon as remembered on the same day, but do not double the dose. Do not take a missed dose on the following day. Skip the missed dose and resume the regular dosing schedule.
None.
Advise the patient to read the FDA-approved patient labeling (Patient Information). Drug Interactions Advise patients and/or caregivers to inform their healthcare provider of all the medicines the patient is taking, including over-the-counter medicines, dietary supplements, and herbal products (e.g., St. John’s Wort), and if there is a change (e.g., discontinuing) in their medication [see Dosage and Administration (2.2, 2.3), Drug Interactions (7.1, 7.2)]. Instruct patients who are initiating JUVMO when concomitantly taking a moderate CYP3A inducer how to properly administer the titration packs. Hypotension/Orthostatic Hypotension Advise patients that they may develop postural (orthostatic) hypotension with or without symptoms such as dizziness, nausea, falling, fainting, or blackouts, and sometimes sweating. Hypotension and/or orthostatic symptoms may occur more frequently during initial therapy or with an increase in dose at any time. Instruct patients to rise slowly after sitting or lying down while using JUVMO [see Warnings and Precautions (5.1)]. Impulse Control/Compulsive Behaviors Advise patients and their caregivers that patients may experience intense urges to spend money uncontrollably, intense urges to gamble, increased sexual urges, binge or compulsive eating, and/or other intense urges and the inability to control these urges while taking JUVMO alone or with one or more medication(s) for the treatment of Parkinson’s disease. Advise patients that they should report any of these adverse reactions to their healthcare provider [see Warnings and Precautions (5.2)]. Hallucinations/Psychotic Behavior Inform patients that they may experience hallucinations (unreal visions, sounds, or sensations) and other symptoms of psychosis while taking JUVMO. Advise patients that they should report any of these adverse reactions to their healthcare provider [see Warnings and Precautions (5.3)]. Dyskinesia Inform patients that JUVMO may cause or exacerbate pre-existing dyskinesias [see Warnings and Precautions (5.4)]. Marketed by: AbbVie Inc. North Chicago, IL 60064 U.S.A. JUVMO and its design are trademarks of Cerevel Therapeutics, LLC, an AbbVie company. ©2026 AbbVie. All rights reserved. 20095842 PATIENT INFORMATION JUVMO™ (joov’-moh) (tavapadon) tablets, for oral use What is JUVMO? JUVMO is a prescription medicine used for the treatment of Parkinson’s disease (PD) in adults. It is not known if JUVMO is safe and effective in children. Before taking JUVMO, tell your healthcare provider about all your medical conditions, including if you: • have low blood pressure (hypotension), or if your blood pressure decreases when standing (orthostatic hypotension). • have or have had unusual urges such as problems with gambling, compulsive eating, compulsive shopping, and increased sex drive. • have a mental health problem, such as psychosis. • have seen or have been seeing things that are not there, hearing sounds, or feeling sensations that are not real (hallucinations). • have trouble controlling your muscles (dyskinesia). • are pregnant or plan to become pregnant. It is not known if JUVMO will harm your unborn baby. • are breastfeeding or plan to breastfeed. It is not known if JUVMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take JUVMO. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicine, vitamins, and herbal supplements. JUVMO and certain other medicines may affect each other and how they work. Know the medicines you take. Keep a list of them and show your healthcare provider and pharmacist when you get a new medicine. How should I take JUVMO? • Take JUVMO exactly as your healthcare provider tells you to. • Your healthcare provider may change your dose if needed. • Take JUVMO by mouth with or without food. • If you miss a dose of JUVMO, take it as soon as you remember on the same day, but do not take 2 doses at one time. If you do not remember until the following day, skip the missed dose and take JUVMO at your regular time. • If you take too much JUVMO, call your healthcare provider or go to the nearest hospital emergency room right away. What should I avoid while taking JUVMO? • Do not change your body position too fast. Get up slowly from sitting or lying down. JUVMO can lower your blood pressure, which can cause nausea, sweating, dizziness, falling, or fainting when you stand up too quickly. What are the possible side effects of JUVMO? JUVMO may cause serious side effects, including: • low blood pressure. This is a common side effect and may be serious. JUVMO can lower your blood pressure and make you feel dizzy, especially when you stand up (orthostatic hypotension). To help avoid this, do not get up too fast from sitting or after lying down. You may be more likely to feel dizzy after starting JUVMO or when your dose is increased. • unusual urges. Some people taking certain medicines to treat PD, including JUVMO, have had unusual urges. This may include gambling, compulsive eating, compulsive shopping, and increased sex drive. If you or your family members notice that you are having unusual urges or behaviors, talk to your healthcare provider. • seeing things that are not there, hearing sounds, or feeling sensations that are not real (hallucinations). This is a common side effect and may be serious. Hallucinations can happen in people who use JUVMO. Tell your healthcare provider if you have hallucinations. • uncontrolled sudden movements (dyskinesia). This is a common side effect and may be serious. If you have new dyskinesia, or your dyskinesia gets worse, tell your healthcare provider. This may be a sign that your dose of JUVMO or other medicines to control your PD may need to be adjusted. The most common side effects of JUVMO include: • nausea • headache • change in taste • feeling tired (fatigue) • vomiting • dry mouth • anxiety Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of JUVMO. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store JUVMO? • Store JUVMO at room temperature between 68°F to 77°F (20°C to 25°C). Keep JUVMO and all medicines out of the reach of children. General information about the safe and effective use of JUVMO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use JUVMO for a condition for which it was not prescribed. Do not give JUVMO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about JUVMO that is written fo r health professionals. What are the ingredients in JUVMO? Active ingredient: tavapadon Inactive ingredients: 0.25 mg and 1 mg tablets contain: lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, red iron oxide, sodium starch glycolate, talc, titanium dioxide, and yellow iron oxide. 5 mg, 10 mg, and 15 mg tablets contain: carmine, FD&C Blue No. 2, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, sodium starch glycolate, talc and titanium dioxide. Marketed by: AbbVie Inc., North Chicago, IL 60064 U.S.A. ©2026 AbbVie. All rights reserved. JUVMO and its design are trademarks of Cerevel Therapeutics, LLC, an AbbVie company. For more information, call 1-888-817-4847 or go to www.JUVMO.com. This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 9/2026 20095842
7.1 Effect of Other Drugs on JUVMO Table 6 describes drug interactions where concomitant use of another drug affects the use of JUVMO. Table 6: Drug Interactions: Concomitant Use of Other Drugs that Affect the Use of JUVMO Strong and Moderate CYP3A Inhibitors Prevention or Management If JUVMO is used with a strong or moderate CYP3A inhibitor during JUVMO maintenance, reduce JUVMO dosage frequency [see Dosage and Administration (2.2)]. Mechanism and Clinical Effect(s) Tavapadon is CYP3A substrate. Concomitant use of strong and moderate CYP3A inhibitors increase the exposure of tavapadon, which may increase the risk of adverse reactions [see Clinical Pharmacology (12.3)]. Concomitant use of strong CYP3A inhibitors may increase the risk of hallucinations [see Warnings and Precautions (5.3), Clinical Pharmacology (12.3)]. Strong and Moderate CYP3A Inducers Prevention or Management Concomitant use of JUVMO with a strong CYP3A inducer is not recommended [see Dosage and Administration (2.3)]. If JUVMO is used in a patient already on a long-term moderate CYP3A inducer, increase JUVMO dosage frequency [see Dosage and Administration (2.3)]. Mechanism and Clinical Effect(s) Tavapadon is CYP3A substrate. Concomitant use of strong or moderate CYP3A inducer decreases the exposure of tavapadon which may result in reduced JUVMO efficacy [see Clinical Pharmacology (12.3)]. 7.2 Effect of JUVMO on Other Drugs Table 7 describes drug interactions where JUVMO affects concomitant use of another drug. Table 7: Drug Interactions: JUVMO Affecting Other Drugs with Concomitant Use CYP3A Substrates Prevention or Management Consider a dose modification of sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, as clinically appropriate, when initiating or discontinuing JUVMO. Mechanism and Clinical Effect(s) JUVMO is an inducer of CYP3A [see Clinical Pharmacology (12.3)]. Concomitant use of JUVMO may decrease the concentrations of CYP3A substrates. CYP2C8 Substrates Prevention or Management Consider a dosage reduction of sensitive CYP2C8 substrates or CYP2C8 substrates where minimal concentration changes may increase the risk of severe adverse reactions, as clinically appropriate, when concomitantly used with JUVMO. Mechanism and Clinical Effect(s) JUVMO is an inhibitor of CYP2C8 [see Clinical Pharmacology (12.3)]. Concomitant use of JUVMO may increase the plasma concentrations of CYP2C8 substrates. BCRP Substrates Prevention or Management Consider a dosage reduction of BCRP substrates, as clinically appropriate, when concomitantly used with JUVMO. Mechanism and Clinical Effect(s) JUVMO is an inhibitor of efflux transporter BCRP [see Clinical Pharmacology (12.3)]. Concomitant use of JUVMO may increase the exposure of BCRP substrates.
Carcinogenesis Carcinogenicity studies of tavapadon were conducted in Tg.rasH2 mice at oral doses of 10, 30 and 100 mg/kg/day for up to 26-weeks and in male and female rats at oral doses of 5, 15, 50 mg/kg/day and 2, 10, 120 mg/kg/day, respectively, for up to 2 years. In the 26-week study, mice had an increased incidence of hepatocellular adenomas at 100 mg/kg/day. In the 2-year study in rats, female rats exhibited an increase in pancreatic and whole body adenocarcinoma at the high dose 120 mg/kg/day. Tavapadon exposure at this dose was 14-fold greater than the exposure at the MRHD. Male rats had an increased incidence of Leydig cell tumors at ≥ 15 mg/kg/day, and female rats showed increased incidences of uterine/cervical tumors at ≥ 10 mg/kg/day. The endocrine mechanism involved in the production of these tumors (prolactin reduction) in rats is not considered relevant to humans. Mutagenesis Tavapadon was not mutagenic or clastogenic in in vitro (bacterial mutagenicity and micronucleus TK6 cells) and in vivo (rat peripheral blood micronucleus) assays. Impairment of Fertility Tavapadon was orally administered to male (15, 50, 150 mg/kg/day) and female (0.5, 1.5, or 5 mg/kg/day) rats prior to and during mating and continuing in females through gestation day 7. There were no adverse effects on fertility or reproductive performance. Plasma exposures (AUC) at the highest dose tested are approximately 9.3 times (males) and 3.1 times (females) the MRHD.
Risk Summary There are no adequate data on the developmental risk associated with the use of JUVMO in pregnant women. In animal studies, administration of tavapadon during organogenesis (rats and rabbits) did not result in adverse developmental effects at exposures greater than those used clinically (see Data). Following administration of tavapadon throughout pregnancy and lactation (rats), there were adverse effects on postnatal growth at exposures 7 times those used clinically (see Data). The estimated background risk of major birth defects and of miscarriage in the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data There were no adverse embryo-fetal development effects following oral administration of tavapadon to pregnant rats (5, 15 and 120 mg/kg/day) and rabbits (1, 3 and 10 mg/kg/day) during organogenesis at the 120 mg/kg/day dose in rats (10.3 times the human AUC at the maximum recommended human dose [MRHD]) or the 10 mg/kg/day dose in rabbits (1.8 times the human AUC at the MRHD). Oral administration of tavapadon to rats (5, 15, or 120 mg/kg/day) throughout gestation and lactation resulted in a reversible decrease in female pup body weights at 120 mg/kg/day. In male pups, there was a delay in preputial separation at all doses.
Safety and effectiveness in pediatric patients have not been established.
Of the 1,279 patients who received JUVMO in clinical studies, 691 (54%) were ≥ 65 years of age and 166 (13%) were ≥ 75 years of age. Patients aged 65 years and older who are treated with JUVMO are at an increased risk of hallucinations [see Warnings and Precautions (5.3)].
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: • Hypotension/Orthostatic Hypotension [see Warnings and Precautions (5.1)] • Impulse Control/Compulsive Behaviors [see Warnings and Precautions (5.2)] • Hallucinations and Psychotic-like Behavior [see Warnings and Precautions (5.3)] • Dyskinesia [see Warnings and Precautions (5.4)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of JUVMO was evaluated in 1,279 patients with PD who received at least one dose of JUVMO. Of the patients with PD who received JUVMO, 870 were treated for at least 6 months and 630 were treated for at least 1 year. JUVMO without Concomitant Levodopa Study 1 evaluated fixed doses of once daily JUVMO 5 mg (n=177) and JUVMO 15 mg (n=177) compared to placebo (n=175). Study 2 evaluated doses of JUVMO 5 mg to 15 mg unless prevented by intolerance (n=151) compared to placebo (n=153) [see Clinical Studies (14.1)]. In Study 1 and Study 2 combined (n=833 total patients), the most common adverse reactions that occurred in ≥ 5% of patients treated with JUVMO were nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth, and anxiety. Adverse reactions led to discontinuation of JUVMO in 100 of 505 patients (20%). Of the 100 patients receiving JUVMO who discontinued because of an adverse reaction, 85 (85%) did so during the titration and/or adjustment phases. The most common adverse reactions leading to discontinuation in patients taking JUVMO were nausea, dizziness, headache, and vomiting. Table 4 presents the adverse reactions that occurred in ≥ 3% of patients treated with JUVMO and with a difference of ≥ 2% between the JUVMO and the placebo group in Study 1 and Study 2. Table 4: Adverse Reactions that Occurred in ≥ 3% of Patients with Parkinson’s Disease Treated with JUVMO and ≥ 2% Difference from Placebo in Study 1 and Study 2 (without Concomitant Levodopa) Adverse Reaction JUVMO Placebo (N=505) % (N=328) % Nausea 27 2 Headachea 17 5 Dizziness 14 4 Fatigueb 10 3 Dysgeusia 8 0 Vomiting 7 <1 Dry mouth 5 <1 Anxiety 5 2 Hypotension 4 1 Dyspepsia 4 1 Abnormal dreams 4 <1 Orthostatic hypotension 4 <1 Hallucinationc 3 0 Gastroesophageal reflux disease 3 <1 Constipation 3 1 a Headache includes multiple related terms b Fatigue includes asthenia c Hallucination includes multiple related terms JUVMO with Concomitant Levodopa Patients in Study 3 were on a fixed dose of levodopa and were titrated to JUVMO 15 mg once daily unless prevented by intolerance, resulting in maintenance doses between 5 mg and 15 mg (n=251), compared to placebo (n=254). The most common adverse reactions that occurred in ≥ 5% of patients treated with JUVMO were nausea, dyskinesia, dizziness, headache, hallucinations, and orthostatic hypotension. Adverse reactions led to discontinuation of JUVMO in 43 of 251 patients (17%). Of the 43 patients receiving JUVMO who discontinued because of an adverse reaction, 38 (88%) did so during the titration and adjustment phases. The most common adverse reactions leading to discontinuation included nausea, dyskinesia, visual hallucination, and dizziness. Table 5 summarizes the adverse reactions that occurred in ≥ 3% of patients who received JUVMO and with a difference of ≥ 2% between the JUVMO and the placebo groups in Study 3. Table 5: Adverse Reactions that Occurred in ≥ 3% of Patients with Parkinson’s Disease Treated with JUVMO and ≥ 2% Difference from Placebo in Study 3 (with Concomitant Levodopa) Adverse Reaction JUVMO Placebo (N=251) % (N=254) % Nausea 14 4 Dyskinesia 10 2 Dizziness 8 3 Headachea 7 3 Hallucinationb 7 1 Orthostatic hypotension 6 1 Hypotension 4 <1 Abdominal pain 3 <1 Asthenia 3 0 a Headache includes multiple related terms b Hallucination includes multiple related terms
September 25, 2026
Type: ORIG · Priority: STANDARD · Class: 7